One near-term rival is Johnson & Johnson's FcRn inhibitor nipocalimab, which started a phase 3 programme last December.

Haematological cancers are a recognised potential side effect with Skysona and were already mentioned in a boxed warning on the gene therapy's approved labelling. The new label restricts use of the ...

One major and often overlooked factor contributing to this imbalance is the way health outcomes are measured in clinical ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...

More details have emerged of a UK plan for new medicines to get simultaneous decisions from the MHRA and NICE on their use by the NHS.

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.

OpenEvidence has raised $210m to expand the capabilities of its physician decision-making tool and launch a new service offering 'PhD-level' research.

AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.

The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million.

The White House has confirmed that the trade deal signed with the EU – which includes an overarching tariff rate of 15% on imports into the US – does extend to most pharmaceutical products ...

At ASCO 2025 in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Dr Jason Williams, director of interventional ...